Qualitative and quantitative assessment of how biomarkers can change the diagnostic and commercial landscape in Alzheimer’s disease. The analysis provides an outline of the opportunities for drug and diagnostics companies in the Alzheimer’s market.
Diversification is one strategy Big Pharma is using to contend with the oncoming patent cliff, however, Datamonitor has analyzed ten sectors within healthcare and concluded that remaining pharma-focused will lead to maximum revenue growth.
Edit my basket
© Datamonitor 2012. All rights reserved
Terms & Conditions